多药耐药相关蛋白在肾母细胞瘤中的表达及临床意义

目的 :观察多药耐药相关蛋白 (MRP)在肾母细胞瘤中的表达情况 ,探讨其临床意义。方法 :采用免疫组织化学方法检测 48例肾母细胞瘤、3 6瘤旁肾组织及 14例正常肾组织 (6例胚胎肾、8例重肾组织 )中MRP的表达。结果 :肾母细胞瘤中阳性表达 8例 ,占 16.7% ,瘤旁肾组织中阳性表达 2 2例 ,占 61.1% ,两者差异显著 (P <0 .0 1)。正常肾组织阳性表达者 3例 ,占 2 1.4% ,同瘤旁肾组织组比较差异显著 (P <0 .0 5 )。预后差者 9例 (复发6例 ,死亡 3例 ) ,阳性表达者 5例 ,占 5 5 .6% ,与预后良好者比较 ,差异显著 (P<0 .0 5 )。结论 :MRP在肾母细胞瘤中表达率低于瘤旁组织 ,从蛋白水平上为肾母细胞瘤化疗提供了依据 ,并可以作为判定预后的指标

Expression of Multidrug Resistance-Associated Protein in Nephroblastoma

Objective: Our aims were to examine the expression of multiple drug resistance associated protein (MRP) in nephroblastoma and to discuss the drug resistance function and clinical significance. Methods: We investigiated the expression of MRP in 48 cases of nephroblastoma, 36 cases of corresponding para tumor tissue, and 14 cases of healthy kidney tissue with the technique of immunohistochemistry. Results: Eight(16.7%)cases of nephroblastoma had positive expression of MRP, 22(61.1%)cases of para tumor of nephroblastoma had positive expression of MRP. The protein expression discrepancy was significant (P<0.01). Five(55.6%) cases were MRP positive in 9 patients with poor prognosis.Campared with the patients having good prognosis, the discrepancy was significant (P<0.05). Conclusion: The significant protein expressing discrepancy had provided theoretical proof for the chemical drug therapy in pre and post operation in nephroblastoma.